Scientists at the University of Oxford say their experimental COVID-19 vaccine shows а strong immune response among older people.牛津大学的科学家表示，他们的实验性新冠肺炎疫苗在老年人中显示出强烈的免疫反应。The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.早期的研究结果燃起了人们的希望，即希望疫苗能够保护重症风险最大的人群免受新冠病毒侵袭。Dr. Andrew Pollard leads the University of Oxford study.安德鲁.波拉德博士领导牛津大学的相关研究。Hе told the British Broadcasting Corporation (BВC) on Thursday that he was "delighted" that early results show a strong immune response " even in those over 70 years of age."周四， 他对英国广播公司(BBC) 表示，他对早期结果显示的“即使是70岁以上的人”也有强烈的免疫反应感到“高兴”。Dr Maheshi Ramasamy of the Oxford Vaccine Group added that the next step will be to see if the immune response means protection from the disease itself.牛津疫苗小组的玛赫希拉玛萨米博士补充表示，下一步将观察免疫反应是否意味着对疾病本身的保护。The results came from а Phase 2 study of 56о volunteers, including 240 people aged 70 or older.研究结果来自于-项针对560名志愿者的第二阶段研究，包括240名70岁以上的高龄者。One group of the volunteers was given two treatments of the vaccine, called ChAdOx1.其中一组志愿者接受了两次被称为ChAdOx1的疫苗治疗。The other group was given a placebo - a shot with an inactive substance.另一组服用安慰剂，被注射一-种非活性物质。Findings from the study were published Thursday in the medical paper The Lancet for scientific review.周四，这项研究中的新发现被发表在的医学论文杂志《柳叶刀》上。The Oxford vaccine uses а harmless, weakened adenovirus to carry genetic material from the new coronavirus into thebody.牛津大学的疫苗使用一种无害 、弱化的腺病毒将新冠病毒的遗传物质带入人体。The human cells will then create proteins to develop antibodies against the coronavirus.人类细胞将产生形成抗体的蛋白质来抵抗新冠病毒。These so-called adenovirus vector vaccines are not known to cause any serious healthconcerns.这些所谓的腺病毒载体疫苗并不会引起任何严重的健康问题。Working with drug-maker AstraZeneca, Oxford is currently carrying out its Phase 3study.牛津大学与阿斯利康制药公司合作，目前正在进行第三阶段研究。The study includes 60,000 volunteers from Britain, the United States, Russia and Brazil, among other countries.来自英国、美国、俄罗斯和巴西等国的6万名志愿者参与了这一研究。The Oxford study was briefly suspended in September because of an unexplained illness in a volunteer.9月，因一名志愿者出现不明原因的疾病，牛津大学暂停这项研究。Pollard said he expects to release all data from the Phase 3 study by late December.波拉德表示，他预计将在12月底公布第三阶段研究的所有数据。Earlier this week, two American drug-makers announced that their separate COVID-19 vaccine candidates were 95 percent effective against the disease.本周早些时候，两个美国制药商宣布各自的新冠肺炎候选疫苗对此疾病有95%的疗效。The companies, Moderna and Pfizer, have said they will seek emergency use authorization for their vaccines from the U.S. Food and Drug Administration (FDA).两家公司一莫 德纳和辉瑞已表示，将向美国政府争取疫苗的紧急使用权。食品和药物管理局(FDA)，Pfizer developed its vaccine with German partner BioNTech.辉瑞公司与德国合作伙伴BioNTech合作开发了此疫苗。Moderna and Pfizer have not yet published results from their studies in medical papers for review.莫德纳公司和辉瑞公司还没有在医学论文中发表他们的研究结果以供审查。Pollard said there was "no competition" with other vaccines.波拉德表示，不会与其他疫苗“竞争”。Hе said, "We will need all of them to protect people around the globe."“我们需要所有疫苗来保护全球人民。”
